EU MDR · implant definition · Rule 8 · lifecycle evidence
Build the implant pathway around tissue contact, duration and clinical risk
Implantable status is more than a product label. It changes the classification analysis, clinical evidence strategy, notified-body review, patient information and post-market obligations that must remain connected throughout the device lifecycle.
Start with Article 2
Confirm why the product is an implant before assigning a class
An implantable device is introduced into the human body by a clinical intervention and is intended to remain after the procedure. A device that is only partly introduced is also implantable when it is intended to remain for at least 30 days. Products replacing an epithelial surface or the surface of the eye are included when they remain in place after the procedure.
Completely introduced
The device is totally introduced into the body by a clinical intervention and is intended to remain after that procedure.
Partly introduced long term
Only part of the device is introduced, but the introduced part is intended to remain for at least 30 days after the intervention.
Surface replacement
The device replaces an epithelial surface or the surface of the eye and remains in place after the clinical intervention.
Two distinctions prevent early classification errors
The intended purpose, anatomical placement, duration and removal conditions should therefore be fixed in the product definition before Rule 8 is applied.
Annex VIII classification
Rule 8 starts at class IIb and then branches by location and risk
Rule 8 is not a single class assignment. It contains a class IIa branch for devices placed in the teeth, a class IIb baseline and defined class III escalations. Other applicable rules still have to be assessed, and the strictest resulting class prevails.
Placed in the teeth
The specific Rule 8 branch applies to implantable or long-term surgically invasive devices intended to be placed in the teeth.
Confirm materials, patient-contact profile and every other applicable rule.General implant baseline
Implantable devices and long-term surgically invasive devices are class IIb unless a specific Rule 8 condition or another rule changes the result.
The classification rationale must describe the actual device, not only its family name.Specified higher-risk categories
- Direct contact with the heart, central circulatory system or central nervous system
- Biological effect, full or main absorption, chemical change in the body or medicinal-product administration
- Active implantable devices and their accessories
- Breast implants and surgical meshes
- Total or partial joint replacements, subject to the stated component exception
- Spinal disc replacements and implants contacting the spinal column, subject to the stated component exception
Names such as “screw”, “plate” or “connector” do not automatically establish the class. Intended purpose, anatomical site, mode of action, duration and whether the item is an accessory must be resolved for the marketed configuration.
Conformity pathway
Make classification drive the review plan, not merely the label
Class IIb and class III implants both require notified-body involvement, but the depth and structure of technical-documentation review differ. Clinical evidence, risk control and manufacturing controls must describe the same released configurations.
-
01
Define the marketed implant
Fix intended purpose, users, anatomy, duration, variants, accessories, materials and active functions.
-
02
Classify every configuration
Apply Rule 8 and all other relevant Annex VIII rules to the product that will actually be placed on the market.
-
03
Build the evidence architecture
Connect GSPR compliance, risk controls, design verification, biological safety and clinical evidence.
-
04
Plan notified-body review
Select the conformity-assessment route and identify device-specific review, sampling and any consultation procedure.
-
05
Control market entry
Complete certification, declaration, CE marking, UDI and registration activities with the correct labelling package.
-
06
Feed use data back into evidence
Use PMS, vigilance, PMCF and trend data to maintain risk management and clinical evaluation.
Review implications
Notified-body conformity assessment is required. Under Article 52, technical documentation is generally assessed for every device, with a defined exception for listed well-established technologies.
The highest MDR class applies. Device technical documentation and clinical evidence receive direct review, and the Article 54 clinical evaluation consultation procedure may apply unless an exemption is met.
Evidence system
Test the implant as a biological, mechanical and clinical system
Verification cannot be divided into unrelated reports. Each study should identify the released design, worst-case configuration, manufacturing state, acceptance criteria and the risk controls it supports.
Biological safety and materials
Characterisation, toxicological assessment, degradation, corrosion, wear debris, leachables and tissue-contact duration.
Mechanical performance
Strength, fatigue, fixation, migration, wear, fracture modes and simulated-use loads over the claimed lifetime.
Sterility and microbiology
Sterilisation validation, bioburden, endotoxin where relevant, packaging integrity and reprocessing controls for instruments.
Clinical evidence
State-of-the-art comparison, benefit-risk endpoints, clinical investigation where required, equivalence limits and PMCF.
Procedure and usability
Implantation workflow, sizing, positioning, compatible instruments, user training and foreseeable procedural errors.
Interactions and active functions
MR safety, electromagnetic compatibility, power and battery behaviour, telemetry, alarms, software and cybersecurity where applicable.
Packaging and shelf life
Transport, sterile-barrier integrity, ageing, storage conditions and performance at the end of the labelled shelf life.
Traceability and change control
Basic UDI-DI, UDI, device identifiers, supplied components and assessment of changes to design, materials, suppliers or processes.
Clinical evidence over time
Treat CE marking as a controlled evidence transition
Article 61 generally expects clinical investigations for implantable and class III devices. Its exceptions are conditional. They do not turn literature or equivalence into an automatic substitute for device-specific data.
Clinical evaluation plan
Define safety, performance and benefit-risk questions before selecting evidence.
Pre-market evidence
Combine investigation data and other justified sources with explicit relevance and limitations.
PMCF and PMS
Collect experience needed to confirm long-term performance and detect emerging risks.
Controlled updates
Update the clinical evaluation, risk file, PMCF evaluation and SSCP with the resulting evidence.
Equivalence is evidence, not resemblance
Technical, biological and clinical characteristics must support the comparison. Access to the information needed for a robust assessment must be demonstrated where MDR equivalence is relied upon.
SSCP communicates the maintained evidence
Implantable and class III devices require an SSCP, except custom-made and investigational devices. It is validated by the notified body and complements rather than replaces the IFU and implant-card information.
Article 18 information
Design patient information as part of device traceability
The implant card and accompanying information should let the patient and healthcare professional identify the implant and act on warnings, environmental interactions, expected lifetime and required follow-up. Health institutions add the patient and implantation details.
- Device
- name · model · identifier
- Traceability
- UDI · serial or lot number
- Manufacturer
- name · address · website
- Procedure
- patient and implantation details
Information accompanying the card
- Warnings, precautions and measures for foreseeable external influences, examinations and environmental conditions
- Expected device lifetime and necessary follow-up
- Information needed by the patient for safe use
- Language and access method required in the relevant Member State
Article 18 exempts sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors from its implant-card obligations. The exemption does not remove other labelling, traceability, clinical or post-market requirements.
EU and US planning
Keep one product definition, but do not export one market’s classification
The evidence architecture can support more than one jurisdiction, but market classification and submission routes remain separate legal decisions.
MDR conformity assessment
Apply the MDR implant definition and Annex VIII rules, then align GSPR evidence, quality-system controls, clinical evaluation and the notified-body route with the resulting class.
Typical outputsClassification rationale · technical documentation · clinical evaluation · CE certification · PMS and PMCF
FDA device-specific pathway
Identify the device type, classification regulation, product code, applicable controls and predicate landscape. An implant may follow an exempt, 510(k), De Novo or PMA route depending on the device.
Typical outputsRegulatory classification · submission strategy · verification and validation · establishment and device obligations
Primary sources
Verify the device-specific route against the current source text
Frequently asked questions
Practical implant distinctions
The final route depends on the actual implant, its marketed configurations and the evidence available for its intended purpose.
Are all implantable devices class III under the MDR?
No. Rule 8 uses class IIb as the general implant baseline, class IIa for devices placed in the teeth and class III for specified higher-risk categories. All applicable classification rules still need to be assessed.
Is a clinical investigation always required?
The MDR generally requires clinical investigations for implantable and class III devices. Article 61 contains defined exceptions and conditions, so the manufacturer must justify the legal route and demonstrate that the evidence is sufficient for the specific device.
Does every implant require an implant card?
No. Article 18 lists exemptions for sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors. Other applicable MDR obligations remain.
What is the SSCP for an implantable device?
The summary of safety and clinical performance is a public, notified-body-validated summary for implantable and class III devices, other than custom-made or investigational devices. It complements rather than replaces the IFU or implant-card information.
Can an EU class be reused for the United States?
No. The FDA route follows the identified device type, classification regulation, product code, controls and predicate landscape. Depending on the device, the route may be exempt, 510(k), De Novo or PMA.